Introducing ICD-85 (Venom derived peptides) as an anti-cancer agent
Publish place: 8th International Breast Cancer Congress
Publish Year: 1391
نوع سند: مقاله کنفرانسی
زبان: English
View: 515
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ICBCMED08_006
تاریخ نمایه سازی: 29 فروردین 1397
Abstract:
The three major forms of cancer treatment are surgery, radiation therapy andchemotherapy. But most cancer patients treated with these three means remainsincurable. Our studies revealed an inhibitory effect of ICD-85 (Venom derivedpeptides) on breast cancer cell line MDA-MB231. ICD-85 was also confirmedby in vivo studies to suppress the breast tumor in mice. The characteristic DNAladder formation of ICD-85 treated cells in agarose gel electrophoresisconfirmed that ICD-85 inhibited the cancer cell proliferation by inducing cellapoptosis. Also, the apoptosis-induction mechanism by ICD-85 on cancer cellswas found through activation of caspase-8. Based on the results obtained inanother study, ICD-85 has an anti-angiogenic activity with dose-dependentmanner. Encapsulation of ICD-85 with sodium alginate nanoparticles reducedits necrotic effect on primary lamb kidney cells. Absorption ratio of I131labeled ICD-85 in breast tumor verses various organs in mice after 45 minindicated the maximum accumulation of ICD-85 in breast tumor and later inkidney. Based on these studies the ICD-85 can be considered as a new agent incancer treatment and we hope to get attention of oncologists for phase 0 ofclinical trial in cancer patients.
Keywords:
Authors
Abbas Zare Mirakabadi
Razi Vaccine and Serum Research Institute, Karaj, Iran
Pezhman Shirmardi
Razi Vaccine and Serum Research Institute, Karaj, Iran
Ali Sarzaeem
Razi Vaccine and Serum Research Institute, Karaj, Iran